Klaus Herfarth, Peter Borchmann, Sven Schnaidt, Karin Hohloch, Volker Budach, Marianne Engelhard, Andreas Viardot, Rita Engenhart-Cabillic, Ulrich Keller, Gabriele Reinartz, Hans-Theodor Eich, Mathias Witzens-Harig, Clemens F Hess, Bernd Dörken, Jan Dürig, Thomas Wiegel, Wolfgang Hiddemann, Eva Hoster, Christiane Pott, Martin Dreyling
The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-arm multicenter phase 2 design. Eighty-five stage I-II FL patients received 8 cycles of Rituximab (375 mg/m2 ) and IF irradiation (30/40 Gy). The primary endpoint was progression-free survival (PFS) 2 years from treatment start. Secondary endpoints were overall survival (OS), complete response rates, toxicity, quality of life, and minimal residual disease (MRD) response with protocol defined visits up to month 30...
December 2018: HemaSphere